VIDEO: Three new treatments relevant to primary care

SAN DIEGO — Gerald W. Smetana, MD, MACP, provided an update on three new treatments that are important to primary care physicians.

Specifically, these include the COVID-19 antiviral Paxlovid (nirmatrelvir/ritonavir, Pfizer) — which is technically only authorized by the FDA for emergency use but is expected to receive approval soon — along with Mounjaro (tirzepatide, Lilly), the first GLP-1 and GIP receptor agonist approved for the treatment of diabetes. He also mentioned zuranolone, a novel antidepressant developed by Biogen and Sage Therapeutics that is expected to be approved later this year.

Smetana, who is an internal medicine and PCP affiliated with Beth Israel Deaconess Medical Center, reviewed the safety and efficacy of all three treatments and offered important context for their use.

References:

• Smetana GW. Newly approved therapies in primary care. Presented at: ACP Internal Medicine Meeting; April 27-29, 2023; San Diego.